Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01855867 · ClinicalTrials.gov registry record · Phase 4
HIV Non-Occupational Post-Exposure Prophylaxis
A Phase 4 study of Human Immunodeficiency Virus, sponsored by Kenneth H. Mayer, MD.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT01855867: Completed Phase 4 study of Human Immunodeficiency Virus, sponsored by Kenneth H. Mayer, MD.
NCT01855867 is a Phase 4 study of Human Immunodeficiency Virus that has completed, run by Kenneth H. Mayer, MD. The registered enrollment target is 100 participants, below the 181-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01855867, a Phase 4 study of Human Immunodeficiency Virus, has completed, sponsored by Kenneth H. Mayer, MD.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if an anti-HIV medication known as Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir DF) is safe, tolerable and acceptable when taken for 28 days, once a day after a possible, sexual, exposure to the Human Immune Deficiency Virus (HIV).
Primary Outcome
The number of adverse events reported
Conditions Studied
Interventions
- DRUG Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)
Study Locations (1)
Massachusetts
- Fenway Community Health - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-04 |
| Phase | Phase 4 |
What the finished NCT01855867 record still lists
NCT01855867 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 181-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 1 intervention - of which Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) is the first listed.
NCT01855867 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01855867 about?
NCT01855867 is a clinical study titled "HIV Non-Occupational Post-Exposure Prophylaxis". The purpose of this study is to see if an anti-HIV medication known as Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir DF) is safe, tolerable and acceptable when taken for 28 days, once a day after a possible, sexual, exposure to the Human Immune Deficiency Virus (HIV).
What is the current status of trial NCT01855867?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2013-05. Estimated completion is 2016-04.
What conditions does trial NCT01855867 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus.
What interventions are being tested in trial NCT01855867?
The interventions under investigation include: Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) (DRUG).
Who is sponsoring clinical trial NCT01855867?
This trial is sponsored by Kenneth H. Mayer, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01855867 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01855867's enrollment target sits among peer trials
100 16th of 39 higher than 22 of 39 other Human Immunodeficiency Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Immunodeficiency Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Low Dose Naltrexone for Pain in Patients With HIV
RECRUITING · Phase 4
-
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
RECRUITING · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
-
Post-Exposure Prophylaxis in Health Care Workers
COMPLETED · Phase 4
-
Biomarkers for Event-driven PrEP Adherence
COMPLETED · Phase 4
-
Switching Undetectables to Selzentry
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia